Plant Name: Vernonia profuga
Taxonomic Information:
Plant ID: NPO17431
Plant Latin Name: Vernonia profuga
Taxonomy Genus: Vernonia
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
434704
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TAAR1; CHRM1; CHRM2; CHRM3; CHRM4; CHRM5; | |
| TSHR; | |
| TDP1; NT5E; RECQL; | |
| ABCC1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | NT5E | 5'-nucleotidase | P21589 | CHEMBL5957 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 1.072E-11 | 2.594E-08 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.532E-08 | 6.167E-05 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 4.075E-07 | 5.220E-04 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.997E-07 | 6.045E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.647E-07 | 6.893E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.647E-07 | 6.893E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.096E-06 | 9.455E-04 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.374E-06 | 2.099E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.272E-06 | 2.943E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 5.621E-06 | 3.060E-03 | CHRM1, CHRM3 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 9.701E-06 | 4.694E-03 | CHRM1, CHRM2, CHRM3 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.572E-05 | 6.864E-03 | CYP1A1, CYP1A2 |
| CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 1.572E-05 | 6.864E-03 | CHRM2, CHRM3 |
| BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 2.020E-05 | 7.997E-03 | CHRM1, CHRM3 |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 1.341E-16 | 1.460E-12 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 1.341E-16 | 1.460E-12 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 8.042E-16 | 5.837E-12 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 4.133E-05 | 1.452E-02 | ABCC1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.305E-10 | 1.857E-08 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, TAAR1, TSHR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.381E-08 | 2.418E-07 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 3.684E-07 | 4.298E-06 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.316E-06 | 2.902E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 8.016E-06 | 5.611E-05 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.027E-05 | 5.993E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.057E-05 | 1.028E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.917E-05 | 1.276E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.042E-04 | 1.572E-03 | CHRM2, CHRM1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.299E-04 | 2.205E-03 | CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.063E-03 | 3.381E-03 | CYP1A2, CYP1A1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| NA: NA | Suprapubic pain | NA | CHRM4; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM4; CHRM5; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | CHRM4; |
| NA: NA | Uveitis | NA | CHRM4; |
| NA: NA | Dystonia | NA | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | CHRM4; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| NA: NA | Addiction | NA | CHRM2; |
| NA: NA | Urgency | NA | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| NA: NA | Dysuria | NA | CHRM4; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; |
| NA: NA | Gastritis | NA | CHRM4; |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| NA: NA | Vomiting | NA | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM4; CHRM5; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CHRM4; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; CHRM4; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4; |
| NA: NA | Peptic ulcer disease | NA | CHRM4; |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; CHRM4; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| NA: NA | Spasms | NA | CHRM3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; CHRM4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
